ID

19178

Description

Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00160693

Lien

https://clinicaltrials.gov/show/NCT00160693

Mots-clés

Versions (1)
  1. 10/12/2016 10/12/2016 -
Téléchargé le

10 décembre 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Rheumatoid Arthritis NCT00160693

Anglais

Eligibility Rheumatoid Arthritis NCT00160693

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
participation in czp trial c87014 or c87011
Description

Study Subject Participation Status | Clinical Trial certolizumab pegol

Type de données

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0008976
UMLS CUI [2,2]
C1872109
if female and of childbearing potential, she agrees to participate in this study by providing written informed consent, has been using adequate contraception since her last menses, will use adequate contraception during the study and for 12 weeks after the last dose of study drug (or longer if required by local regulations), is not lactating, and has had a negative urine pregnancy test on the day of receiving the first dose of study drug
Description

Childbearing Potential Informed Consent | Childbearing Potential Contraceptive methods | Breast Feeding | Childbearing Potential Urine pregnancy test negative

Type de données

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0021430
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0700589
UMLS CUI [3]
C0006147
UMLS CUI [4,1]
C3831118
UMLS CUI [4,2]
C0430057
must have provided written informed consent before undergoing any study procedures
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
history (hx) of chronic infection, serious or life-threatening infection -
Description

Chronic infectious disease | Communicable Disease Serious | Life-threatening infections

Type de données

boolean

Alias
UMLS CUI [1]
C0151317
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C0205404
UMLS CUI [3]
C1859430
(including herpes zoster) within 6 months prior, or any current symptom indicating infection
Description

Herpes zoster disease | Communicable Disease Symptom

Type de données

boolean

Alias
UMLS CUI [1]
C0019360
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C1457887
current or recent hx of severe, progressive and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease
Description

Kidney Disease Progressive Severe | Kidney Disease Uncontrolled | Liver disease | Hematological Disease | Gastrointestinal Diseases | Endocrine System Diseases | Lung diseases | Heart Diseases | nervous system disorder | Cerebral disorder

Type de données

boolean

Alias
UMLS CUI [1,1]
C0022658
UMLS CUI [1,2]
C0205329
UMLS CUI [1,3]
C0205082
UMLS CUI [2,1]
C0022658
UMLS CUI [2,2]
C0205318
UMLS CUI [3]
C0023895
UMLS CUI [4]
C0018939
UMLS CUI [5]
C0017178
UMLS CUI [6]
C0014130
UMLS CUI [7]
C0024115
UMLS CUI [8]
C0018799
UMLS CUI [9]
C0027765
UMLS CUI [10]
C0234387
any finding indicative of tuberculosis at end of previous study
Description

Indication Tuberculosis

Type de données

boolean

Alias
UMLS CUI [1,1]
C3146298
UMLS CUI [1,2]
C0041296
known hiv infection
Description

HIV Infections

Type de données

boolean

Alias
UMLS CUI [1]
C0019693
persistently abnormal ast (aspartate aminotransferase) or alt (alanine aminotransferase) results (> 2 times upper limit of normal)
Description

AST level abnormal persistent | Alanine aminotransferase (ALT) level abnormal persistent

Type de données

boolean

Alias
UMLS CUI [1,1]
C0580475
UMLS CUI [1,2]
C0205322
UMLS CUI [2,1]
C0580469
UMLS CUI [2,2]
C0205322
hemoglobin (hgb) levels < 9 g/dl or hematocrit < 30 %
Description

Hemoglobin measurement | Hematocrit level

Type de données

boolean

Alias
UMLS CUI [1]
C0518015
UMLS CUI [2]
C0518014
total white blood cell (wbc) count of < 3.0 x 100/l (< 3000/mm^3)
Description

White Blood Cell Count procedure

Type de données

boolean

Alias
UMLS CUI [1]
C0023508
platelet count < 100 x 100 l (100,000/mm^3)
Description

Platelet Count measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0032181
serum creatinine > 1.5 times upper limit of normal based on patient age and sex
Description

Creatinine measurement, serum | Age | Gender

Type de données

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C0001779
UMLS CUI [3]
C0079399
receipt of any biological therapies for ra in 6 months prior to study entry or any prior treatment (tx) with tumor necrosis factor (tnf) blocking agent (excluding cdp870)
Description

Biological treatment Rheumatoid Arthritis | Tumor necrosis factor alpha (TNF-) inhibitors | CDP870

Type de données

boolean

Alias
UMLS CUI [1,1]
C1531518
UMLS CUI [1,2]
C0003873
UMLS CUI [2]
C3653350
UMLS CUI [3]
C1172157
receipt of any vaccination (live, attenuated or killed) in 8 weeks prior to baseline
Description

Vaccination | Vaccines, Attenuated | Vaccines, Inactivated

Type de données

boolean

Alias
UMLS CUI [1]
C0042196
UMLS CUI [2]
C0042211
UMLS CUI [3]
C0042212
any other condition which the principal investigator judges would make patient unsuitable for study participation
Description

Condition Resulting in Study Subject Participation Status Exclusion

Type de données

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0332294
UMLS CUI [1,3]
C2348568
UMLS CUI [1,4]
C2828389
Retour au début de la page

Similar models

Eligibility Rheumatoid Arthritis NCT00160693

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Study Subject Participation Status | Clinical Trial certolizumab pegol
Item
participation in czp trial c87014 or c87011
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2,1])
C1872109 (UMLS CUI [2,2])
Childbearing Potential Informed Consent | Childbearing Potential Contraceptive methods | Breast Feeding | Childbearing Potential Urine pregnancy test negative
Item
if female and of childbearing potential, she agrees to participate in this study by providing written informed consent, has been using adequate contraception since her last menses, will use adequate contraception during the study and for 12 weeks after the last dose of study drug (or longer if required by local regulations), is not lactating, and has had a negative urine pregnancy test on the day of receiving the first dose of study drug
boolean
C3831118 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C0006147 (UMLS CUI [3])
C3831118 (UMLS CUI [4,1])
C0430057 (UMLS CUI [4,2])
Informed Consent
Item
must have provided written informed consent before undergoing any study procedures
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Chronic infectious disease | Communicable Disease Serious | Life-threatening infections
Item
history (hx) of chronic infection, serious or life-threatening infection -
boolean
C0151317 (UMLS CUI [1])
C0009450 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C1859430 (UMLS CUI [3])
Herpes zoster disease | Communicable Disease Symptom
Item
(including herpes zoster) within 6 months prior, or any current symptom indicating infection
boolean
C0019360 (UMLS CUI [1])
C0009450 (UMLS CUI [2,1])
C1457887 (UMLS CUI [2,2])
Kidney Disease Progressive Severe | Kidney Disease Uncontrolled | Liver disease | Hematological Disease | Gastrointestinal Diseases | Endocrine System Diseases | Lung diseases | Heart Diseases | nervous system disorder | Cerebral disorder
Item
current or recent hx of severe, progressive and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease
boolean
C0022658 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,3])
C0022658 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0023895 (UMLS CUI [3])
C0018939 (UMLS CUI [4])
C0017178 (UMLS CUI [5])
C0014130 (UMLS CUI [6])
C0024115 (UMLS CUI [7])
C0018799 (UMLS CUI [8])
C0027765 (UMLS CUI [9])
C0234387 (UMLS CUI [10])
Indication Tuberculosis
Item
any finding indicative of tuberculosis at end of previous study
boolean
C3146298 (UMLS CUI [1,1])
C0041296 (UMLS CUI [1,2])
HIV Infections
Item
known hiv infection
boolean
C0019693 (UMLS CUI [1])
AST level abnormal persistent | Alanine aminotransferase (ALT) level abnormal persistent
Item
persistently abnormal ast (aspartate aminotransferase) or alt (alanine aminotransferase) results (> 2 times upper limit of normal)
boolean
C0580475 (UMLS CUI [1,1])
C0205322 (UMLS CUI [1,2])
C0580469 (UMLS CUI [2,1])
C0205322 (UMLS CUI [2,2])
Hemoglobin measurement | Hematocrit level
Item
hemoglobin (hgb) levels < 9 g/dl or hematocrit < 30 %
boolean
C0518015 (UMLS CUI [1])
C0518014 (UMLS CUI [2])
White Blood Cell Count procedure
Item
total white blood cell (wbc) count of < 3.0 x 100/l (< 3000/mm^3)
boolean
C0023508 (UMLS CUI [1])
Platelet Count measurement
Item
platelet count < 100 x 100 l (100,000/mm^3)
boolean
C0032181 (UMLS CUI [1])
Creatinine measurement, serum | Age | Gender
Item
serum creatinine > 1.5 times upper limit of normal based on patient age and sex
boolean
C0201976 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
Biological treatment Rheumatoid Arthritis | Tumor necrosis factor alpha (TNF-) inhibitors | CDP870
Item
receipt of any biological therapies for ra in 6 months prior to study entry or any prior treatment (tx) with tumor necrosis factor (tnf) blocking agent (excluding cdp870)
boolean
C1531518 (UMLS CUI [1,1])
C0003873 (UMLS CUI [1,2])
C3653350 (UMLS CUI [2])
C1172157 (UMLS CUI [3])
Vaccination | Vaccines, Attenuated | Vaccines, Inactivated
Item
receipt of any vaccination (live, attenuated or killed) in 8 weeks prior to baseline
boolean
C0042196 (UMLS CUI [1])
C0042211 (UMLS CUI [2])
C0042212 (UMLS CUI [3])
Condition Resulting in Study Subject Participation Status Exclusion
Item
any other condition which the principal investigator judges would make patient unsuitable for study participation
boolean
C0348080 (UMLS CUI [1,1])
C0332294 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C2828389 (UMLS CUI [1,4])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial